CANBRIDGE PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.325 HKD | -4.41% |
|
+1.56% | -67.17% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,069 | 918.1 | 382 | 133.9 | - | - |
| Enterprise Value (EV) 1 | 2,376 | 610.3 | 386.5 | 133.9 | 133.9 | 133.9 |
| P/E ratio | -0.63 x | -1.88 x | -1.03 x | -0.53 x | -0.41 x | -0.47 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 98.5 x | 11.6 x | 3.71 x | 1.03 x | 0.89 x | 0.45 x |
| EV / Revenue | 98.5 x | 11.6 x | 3.71 x | 1.03 x | 0.89 x | 0.45 x |
| EV / EBITDA | -4.8 x | -2.11 x | -1.08 x | -0.81 x | -0.7 x | -1.24 x |
| EV / FCF | -5,183,168 x | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - |
| Price to Book | 1.02 x | 2.95 x | -9.75 x | - | - | - |
| Nbr of stocks (in thousands) | 424,192 | 424,292 | 424,562 | 424,838 | - | - |
| Reference price 2 | 8.880 | 2.450 | 0.9900 | 0.3400 | 0.3400 | 0.3400 |
| Announcement Date | 3/22/22 | 3/30/23 | 3/28/24 | - | - | - |
1HKD in Million2HKD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 31.16 | 78.97 | 102.9 | 130 | 150 | 299.7 |
| EBITDA 1 | - | -639.4 | -436 | -353.8 | -166.1 | -191.5 | -107.5 |
| EBIT 1 | - | -655.1 | -476.6 | -369.9 | -192.2 | -222.6 | -136.9 |
| Operating Margin | - | -2,102.46% | -603.52% | -359.57% | -147.83% | -148.42% | -45.69% |
| Earnings before Tax (EBT) 1 | - | -1,077 | -483.5 | -378.8 | -250.5 | -324.1 | -283.9 |
| Net income 1 | -846 | -1,077 | -483.5 | -378.8 | -250.5 | -324.1 | -283.9 |
| Net margin | - | -3,456.26% | -612.21% | -368.26% | -192.67% | -216.03% | -94.73% |
| EPS 2 | -15.11 | -14.04 | -1.302 | -0.9638 | -0.6380 | -0.8260 | -0.7230 |
| Free Cash Flow | - | -592.2 | - | - | - | - | - |
| FCF margin | - | -1,900.31% | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 11/30/21 | 3/22/22 | 3/30/23 | 3/28/24 | - | - | - |
1CNY in Million2HKD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | 4.44 | - | - | - |
| Net Cash position | - | 694 | 308 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -0.0125 x | - | - | - |
| Free Cash Flow | - | -592 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -155% | -96.5% | -282% | - | - | - |
| ROA (Net income/ Total Assets) | - | -146% | - | - | - | - | - |
| Assets 1 | - | 739.4 | - | - | - | - | - |
| Book Value Per Share | - | 8.710 | 0.8300 | -0.1000 | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | 8.5 | - | - | - | - | - |
| Capex / Sales | - | 27.28% | - | - | - | - | - |
| Announcement Date | 11/30/21 | 3/22/22 | 3/30/23 | 3/28/24 | - | - | - |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.34
HKD
Average target price
12.3
HKD
Spread / Average Target
+3,517.65%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -66.16% | 18.49M | |
| +14.35% | 9.26B | |
| -13.94% | 4.92B | |
| +48.58% | 4.66B | |
| +14.10% | 4.27B | |
| +19.66% | 2.44B | |
| -25.55% | 2.22B | |
| +18.39% | 2.15B | |
| -39.57% | 1.89B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- 1228 Stock
- Financials CANbridge Pharmaceuticals Inc.
